There has been little progress in understanding pancreatic ASC since these aggressive tumors were first described over a century ago 1, 2 . One problem is that no mutations unique to this class of pancreatic tumors have been identified. Thus, although oncogenes and tumor suppressor genes have been shown to be altered in ASC-including KRAS and TP53-these same genes are also abnormal in other forms of pancreatic cancer [3] [4] [5] . Here, we report that ASC pancreatic tumors have somatic mutations in Up-frameshift 1 (UPF1), which encodes an RNA helicase essential for the highly conserved RNA degradation pathway, nonsense-mediated RNA decay (NMD) 6 .
We initially investigated the possibility that NMD had a role in ASC because RT-PCR analysis showed that an ASC tumor with wild-type TP53 alleles expressed an abnormally sized p53 band that was not detectable in the adjacent normal pancreas (Supplementary Fig. 1a ). Sequence analysis of this band demonstrated that it was an alternatively spliced TP53 mRNA, generated by the use of a noncanonical splice donor in intron 6 and a noncanonical splice acceptor in intron 10, which both share 14 nucleotides (nt) of sequence identity with the splice donor ( Supplementary Fig. 1b ). Quantitative PCR (qPCR) analysis demonstrated that the alternatively spliced TP53 mRNA was only detectably expressed in tumor tissue, not adjacent normal tissue, whereas the normally spliced TP53 mRNA was expressed at similar levels in the tumor and adjacent normal tissue (Supplementary Fig. 1c) .
The alternative splicing event creating this p53 isoform generates an in-frame premature termination codon (PTC) in intron 6 ( Supplementary  Fig. 1b ). Because NMD degrades mRNAs with PTCs 6,7 , the selective accumulation of this 'alt-PTC-IVS6-p53' mRNA in the tumor tissue but not the adjacent normal tissue raised the possibility that the tumor tissue had deficient NMD. To test this, we screened pancreatic ASC samples for mutations in core NMD genes. We found genomic mutations in the UPF1 gene in pancreatic ASC tumor samples from 18 of 23 patients ( Fig. 1a) , whereas the three other NMD genes we tested-UPF2, UPF3A and UPF3B-did not have detectable mutations (Supplementary Table 1 ). The UPF1 mutations were somatic in origin, as they were not present in matched normal pancreatic tissues from these 18 patients ( Fig. 1a) . UPF1 mutations were also not detectable in 29 non-ASC pancreatic tumors and in 21 lung squamous cell carcinomas that we tested ( Supplementary  Table 2 ). Together, these results suggest that UPF1 mutations are a unique signature of most pancreatic ASCs.
The point mutations in the pancreatic ASC tumors clustered in two regions of the UPF1 gene ( Fig. 1b) . They were nearly equally distributed in the exons and introns in these two regions, raising the possibility that these mutations alter UPF1 splicing by disrupting intronic splicing enhancers (ISEs) and exonic splicing enhancers (ESEs), which are essential for the inclusion of a subset of exons during splicing 8, 9 . In support of this, a subset of the mutations in the ASC tumors disrupted predicted ESEs and ISEs ( Fig. 1b and Supplementary Fig. 2 ). To directly test whether the ASC mutations disrupt UPF1 splicing, we generated UPF1 minigene constructs corresponding to the two regions mutated in ASC tumors ( Fig. 2a,b) . We then introduced, by site-specific mutagenesis, the mutations found in 15 of the patients. Transfection analysis showed that the wild-type versions of the two minigene constructs expressed normally spliced mRNA that included all exons, as determined by direct sequencing of the bands generated by RT-PCR ( Fig. 2c,d) . No other bands were detected, indicating that most of the mRNAs generated by these minigene constructs were normally spliced. In contrast, all 15 mutant minigenes expressed alternatively spliced transcripts ( Fig. 2d) . Although none of the patients' mutations completely eliminated normal splicing, the ratio of alternatively spliced to normally spliced mRNA was 10:1 or higher in many cases. As confirmation, analysis of endogenous UPF1 splicing in two of two frozen tumor samples revealed an alternatively spliced UPF1 mRNA that was not present in the adjacent normal tissue ( Fig. 2e) . We conclude that ASC-specific mutations in the UPF1 gene trigger alternative splicing of UPF1 precursor mRNA.
The UPF1 alternative splicing events caused by mutations in the exon 10 to exon 11 region eliminate a portion of UPF1's RNA The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma Pancreatic adenosquamous carcinoma (ASC) is an enigmatic and aggressive tumor that has a worse prognosis and higher metastatic potential than its adenocarcinoma counterpart.
Here we report that ASC tumors frequently harbor somatically acquired mutations in the UPF1 gene, which encodes the core component of the nonsense-mediated RNA decay (NMD) pathway. These tumor-specific mutations alter UPF1 RNA splicing and perturb NMD, leading to upregulated levels of NMD substrate mRNAs. UPF1 mutations are, to our knowledge, the first known unique molecular signatures of pancreatic ASC. including Staufen-mediated RNA decay 18 . Our finding that UPF1 may be selectively mutated in pancreatic ASC tumors suggests that this feature will be useful for diagnosis of this type of tumor, and it also raises the possibility that patients with ASC can benefit from therapy designed to target NMD substrates 19, 20 .
MeTHoDS
Methods and any associated references are available in the online version of the paper. helicase domain essential for UPF1 function 6 , whereas mutations in the exon 21 to exon 23 region truncate the carboxyterminal region of UPF1, which contains ST-Q motifs phosphorylated by SMG1, a serine-threonine kinase required for NMD 10 (Figs. 1b and 2c) . Given that essential UPF1 domains are lost with these alternative splicing events, the resulting mutant forms of UPF1 are likely to have lost their function or have dominant-negative activity. In the latter case, inhibited NMD would be predicted to occur when only one UPF1 allele is mutated. In support of this possibility, mutations in the RNA helicase domain of UPF1 have previously been shown to confer dominant-negative activity [11] [12] [13] . With regard to the former case, we found that at least one ASC tumor (from patient 22) had mutations in both UPF1 alleles. Several other ASC tumors had multiple UPF1 mutations ( Supplementary Table 1 ), consistent with some of them also having mutations in both UPF1 alleles. In further support of this notion, we observed little or no UPF1 expression in many ASC tumors compared to adjacent normal tissue, as demonstrated by immunohistochemical analysis ( Fig. 2f and Supplementary Table 1 ). As direct evidence that NMD is inhibited in ASC tumors, we found that two NMD substrates, ATF3 and MAP3K14 mRNA 14 , were dramatically upregulated in tumor tissue relative to adjacent normal tissue (Supplementary Fig. 3) .
As perturbation of NMD is known to dysregulate ~3-10% of mRNAs in a variety of cell lines and organisms 6, 14, 15 , it is likely that this will also be the case in pancreatic ASC, which could shift the balance toward a more malignant phenotype 16, 17 . One candidate NMD substrate that could serve in this capacity is the alternatively spliced p53 transcript, alt-PTC-IVS6-p53, that we identified above (Supplementary Fig. 1) , as we found it encoded a protein with dominant-negative activity (Supplementary Fig. 4) .
To our knowledge, the discovery of mutations in the UPF1 gene in ASC tumors represents the first known example of genetic alterations in an NMD gene in human tumors. UPF1 is also the first gene known to be selectively mutated in pancreatic ASC tumors. Other genes mutated in these tumors, including TP53 and K-RAS (Supplementary Fig. 5  and Supplementary Table 1) , are also mutated in other pancreatic tumor types 4, 5 . We note that it is possible that UPF1 mutations in ASC tumors have broad disruptive effects that extend beyond NMD, RefSeq accession number NC_000019.9) was cloned into the NdeI restriction site of the pTBNde minigene construct (pTBNde(mini)). All mutations were generated by site-directed mutagenesis to match those in the indicated patients' tumors. WT, wild type; E, exon. (b) The indicated region of human UPF1 (nt 33,138-34,490) was cloned and mutated as described in a. (c) RT-PCR analysis of HEK 293 cells transfected with the constructs shown in a (primer locations are indicated by the arrows). Direct sequencing of the large (792 nt) and small (239 nt) bands indicated that they correspond to normally spliced (Norm) and exon-skipped (Alt) transcripts, respectively. The numbers below the gel are the average values from five independent transfections. (d) RT-PCR analysis performed as in c. Direct sequencing of the bands in the gel indicated they were derived from mRNA spliced in the manner shown in the schematic. The bands correspond to normally spliced, alternatively spliced variant 1 (alt 1) and alternatively spliced variant 2 (alt 2), which had lengths of 742, 1117 and 619 nt, respectively. The numbers below the gel are the average values from five independent transfections. I, intron. (e) RT-PCR analysis of normal pancreas and ASC frozen samples from patients 15 and 16. RT-PCR sequencing results are indicated as schematics next to the gels. (f) Immunohistochemical analysis of UPF1 staining in ASC tumor samples from patient 15. Tumor (T) and normal tissue (NT) are indicated. Bottom shows H&E staining, with arrows pointing to the adenocarinoma component in this ASC tumor. These images are representative of 16 patients (Supplementary Table 1 ). The scale bar represents 200 µm on each image.
